Hematology
5 drugs are in development for Hemophilia A.
- Companies
- 4
- Clinical trials
- 24
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Hemophilia A pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| eloctate | Bioverativ Inc. (BIVV) |
Preclinical(3)
| Drug | Company |
|---|---|
| dtx201 | Dimension Therapeutics, Inc. (DMTX) |
| dtx601 | Dimension Therapeutics, Inc. (DMTX) |
| p-fviii-101 | Poseida Therapeutics, Inc. (PSTX) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| sig-001 | Sigilon Therapeutics, Inc. (SGTX) |
About this indication
Hemophilia A context
Hematology·MeSH: Hemophilia A (D006467)
Also known as: Classic Hemophilia, Classic Hemophilias, Congenital Hemophilia A, Congenital Hemophilia As, Haemophilia, Hemophilia, Hemophilia As
Prevalence
12.0 / 100K
Incidence
20.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Hemophilia A?
BioSniper tracks 5 drugs in development for Hemophilia A across 4 companies.
How many clinical trials target Hemophilia A?
There are 24 clinical trials targeting Hemophilia A tracked by BioSniper.
What is the prevalence of Hemophilia A?
The estimated prevalence of Hemophilia A is approximately 12.0 per 100,000 population.